Associations between the TNMD rs4828038 and ACE2 rs879922 polymorphisms and preeclampsia susceptibility: a case-control study

Abstract

A case-control study was designed to investigate the association between the angiotensin converting enzyme 2 (ACE2) rs879922, glucose-6-phosphate dehydrogenase (G6PD) rs1050828, and tenomodulin (TNMD) rs4828038 single nucleotide polymorphisms (SNPs), and preeclampsia. A total of 356 Han Chinese pregnant women (170 controls and 186 cases) were recruited into the study. ACE2 rs879922, G6PD rs1050828, and TNMD rs4828038 were tested by the targeted next-generation sequencing technology and the data were analyzed using SPSS version 18. Genotyping of results revealed that patients with the CC/CT genotype in SNP rs4828038 or CC/CG genotype in SNP rs879922 had a significantly decreased susceptibility to late-onset preeclampsia (CC/CT versus TT: OR = 0.543, 95% CI = 0.378 to 0.779, p = .001; CC/CG versus GG: OR = 0.510, 95% CI = 0.038 to 0.860, p = .012). Our study found that the polymorphisms TNMD rs4828038 and ACE2 rs879922 might be associated with late-onset preeclampsia.

IMPACT STATEMENT

• What is already known on this subject? Preeclampsia is associated with multiple SNPs, and ACE2 rs879922, G6PD rs1050828, and TNMD rs4828038 are related to essential hypertension and glucose and lipid metabolism disorders. Essential hypertension, diabetes, and dyslipidemia are risks for preeclampsia. The associations between those three SNPs and preeclampsia have not been reported.

• What do the results of this study add? The polymorphisms of TNMD rs4828038 and ACE2 rs879922 might be associated with the risk of late-onset preeclampsia. There was no relationship between SNP rs1050828 and preeclampsia.

• What are the implications of these findings for clinical practice and/or further research? TNMD rs4828038 and ACE2 rs879922 might be target sites for genetic diagnosis and therapy, and the levels of mRNA and protein in pregnant women with preeclampsia should be further tested.

Keywords:

• Polymorphism
• tenomodulin (TNMD)
• preeclampsia
• glucose-6-phosphate dehydrogenase (G6PD)
• angiotensin converting enzyme 2 (ACE2)

Acknowledgements

The authors involved are indebted to all participants involved for their support and cooperation.

Disclosure statement

All the authors declare that they have met the criteria for authorship and have participated sufficiently in the work to take responsibility for it; reviewed the final version of the manuscript and approve it for submission to the IJGO; neither this manuscript nor one with substantially similar content by the authors has been published elsewhere or is being considered for publication elsewhere; the manuscript has been submitted with the full knowledge and approval of the institutions or organisations given as the affiliation(s) of the author(s); have informed the editor in a cover letter and in the manuscript itself of any conflicts of interest; the corresponding author affirms the manuscript to be an honest and transparent account of the study being reported.

Data availability statement

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Additional information

Funding

Funding for this work was provided by the Jilin Province Science Development Plan [20190304125YY].